$ARCT
Arcturus Therapeutics Holdings Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459020052527 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2019 Q3
Revenue $3.318M
YoY Change -2.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.880M
YoY Change 1.84%
% of Gross Profit
Research & Development $7.053M
YoY Change 77.7%
% of Gross Profit
Depreciation & Amortization $180.0K
YoY Change 12.5%
% of Gross Profit
Operating Expenses $7.053M
YoY Change 77.7%
Operating Profit -$7.616M
YoY Change
Interest Expense $180.0K
YoY Change 80.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.430M
YoY Change 74.82%
Income Tax
% Of Pretax Income
Net Earnings -$7.433M
YoY Change 74.77%
Net Earnings / Revenue -224.02%
Basic Earnings Per Share
Diluted Earnings Per Share -$562.9K
COMMON SHARES
Basic Shares Outstanding 14.27M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.20M
YoY Change 126.22%
Cash & Equivalents $74.17M
Short-Term Investments
Other Short-Term Assets $33.00K
YoY Change -91.75%
Inventory
Prepaid Expenses $2.578M
Receivables $2.600M
Other Receivables $0.00
Total Short-Term Assets $79.40M
YoY Change 130.81%
LONG-TERM ASSETS
Property, Plant & Equipment $7.400M
YoY Change 252.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $303.0K
YoY Change -39.4%
Other Assets $100.0K
YoY Change 0.0%
Total Long-Term Assets $7.815M
YoY Change 189.44%
TOTAL ASSETS
Total Short-Term Assets $79.40M
Total Long-Term Assets $7.815M
Total Assets $87.22M
YoY Change 135.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.013M
YoY Change 38.38%
Accrued Expenses $6.676M
YoY Change 203.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.69M
YoY Change 59.47%
LONG-TERM LIABILITIES
Long-Term Debt $10.02M
YoY Change
Other Long-Term Liabilities $19.60M
YoY Change 108.51%
Total Long-Term Liabilities $10.02M
YoY Change 6.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.69M
Total Long-Term Liabilities $10.02M
Total Liabilities $51.32M
YoY Change 123.13%
SHAREHOLDERS EQUITY
Retained Earnings -$60.68M
YoY Change
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.90M
YoY Change
Total Liabilities & Shareholders Equity $87.22M
YoY Change 135.08%

Cashflow Statement

Concept 2019 Q3
OPERATING ACTIVITIES
Net Income -$7.433M
YoY Change 74.77%
Depreciation, Depletion And Amortization $180.0K
YoY Change 12.5%
Cash From Operating Activities -$2.840M
YoY Change -58.24%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K
YoY Change -36.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$160.0K
YoY Change -102.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.32M
YoY Change -106700.0%
NET CHANGE
Cash From Operating Activities -2.840M
Cash From Investing Activities -160.0K
Cash From Financing Activities 21.32M
Net Change In Cash 18.32M
YoY Change 1713.86%
FREE CASH FLOW
Cash From Operating Activities -$2.840M
Capital Expenditures -$160.0K
Free Cash Flow -$2.680M
YoY Change -59.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36816000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
307130000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74279000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
645000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1988000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21278000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
35895000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
261883000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1461000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3938000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
13642000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1185000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21278000
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201409Member
us-gaap Depreciation And Amortization
DepreciationAndAmortization
613000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
531000
us-gaap Share Based Compensation
ShareBasedCompensation
3938000
us-gaap Share Based Compensation
ShareBasedCompensation
1185000
arct Other Non Cash Interest Expense
OtherNonCashInterestExpense
1027000
arct Other Non Cash Interest Expense
OtherNonCashInterestExpense
649000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
268000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1856000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3872000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1973000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
15000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1489000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7335000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1432000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4236000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10941000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1093000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-503000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21278000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1461000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272944000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36873000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
235670000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37463000
us-gaap Interest Paid Net
InterestPaidNet
173000
us-gaap Interest Paid Net
InterestPaidNet
508000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
674000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5868000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
670000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
126000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74172000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
us-gaap Dividends
Dividends
0
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2179000
arct Contract With Customer Asset Additions For Revenue Recognized
ContractWithCustomerAssetAdditionsForRevenueRecognized
3065000
arct Contract With Customer Asset Deductions For Cash Collections
ContractWithCustomerAssetDeductionsForCashCollections
2797000
CY2020Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2447000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
23579000
arct Contract With Customer Liability Additions For Advanced Billings
ContractWithCustomerLiabilityAdditionsForAdvancedBillings
3065000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7301000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
19343000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4530000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2181000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1608000
CY2019Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
1949000
CY2020Q3 arct Accrued Singapore Economic Development Board Liability
AccruedSingaporeEconomicDevelopmentBoardLiability
2106000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
827000
CY2020Q3 arct Clinical Accruals Current
ClinicalAccrualsCurrent
1352000
CY2019Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
2750000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1300000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7500000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6500000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
600000
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5526998
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
166921
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
96615
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1988000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
383000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P13M
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P1M
CY2020Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease may be extended for one twelve-month period, and in November 2020 the Company deemed the extension option reasonably certain to be exercised and will include the option in the lease terms beginning in October 2020.
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
496000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1427000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1349000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1390000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1432000
CY2020Q3 arct Lessee Operating Leases Liability Payments Due After Year Four
LesseeOperatingLeasesLiabilityPaymentsDueAfterYearFour
314000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6408000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1055000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5353000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
900000

Files In Submission

Name View Source Status
0001564590-20-052527-index-headers.html Edgar Link pending
0001564590-20-052527-index.html Edgar Link pending
0001564590-20-052527.txt Edgar Link pending
0001564590-20-052527-xbrl.zip Edgar Link pending
arct-10q_20200930.htm Edgar Link pending
arct-20200930.xml Edgar Link completed
arct-20200930.xsd Edgar Link pending
arct-20200930_cal.xml Edgar Link unprocessable
arct-20200930_def.xml Edgar Link unprocessable
arct-20200930_lab.xml Edgar Link unprocessable
arct-20200930_pre.xml Edgar Link unprocessable
arct-ex1032_97.htm Edgar Link pending
arct-ex1033_98.htm Edgar Link pending
arct-ex311_7.htm Edgar Link pending
arct-ex312_8.htm Edgar Link pending
arct-ex321_9.htm Edgar Link pending
arct-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending